Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 503

Next Previous
Drug Profile

V 503

Alternative Names: 9-valent HPV vaccine - Merck and Co; 9-valent human papillomavirus vaccine - Merck and Co; 9vHPV vaccine - Merck; GARDASIL; GARDASIL9; Human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; Human Papillomavirus 9-valent vaccine, Recombinant; Human papillomavirus vaccine recombinant 9-valent - Merck; Human papillomavirus vaccine recombinant nonavalent - Merck; Human papillomavirus vaccine-Merck-9 valent; Multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine - Merck; Nonavalent HPV VLP Vaccine; Recombinant HPV 9-valent Vaccine; Recombinant HPV Nonavalent Vaccine; Recombinant Human Papillomavirus 9-valent Vaccine; SILGARD9; V-503

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Banyu; Merck & Co; Takeda
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Cervical cancer; Condylomata acuminata; Head and neck cancer; Human papillomavirus infections; Oropharyngeal cancer; Vulvovaginal cancer
  • Phase III COVID 2019 infections; Dengue

Most Recent Events

  • 28 Feb 2025 Merck Sharp and Dohme completes a phase III trial for Human papillomavirus infections (In adolescents, In adults, Prevention, In volunteers) in China (IM) (NCT03903562)
  • 22 Dec 2024 Phase-III clinical trials in Cervical cancer (Prevention) is ongoing in Malawi, South Africa (IM) (NCT03284866)
  • 11 Sep 2024 Efficacy data from the phase III V503-064 trial in Human papillomavirus infections released by Merck AG

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top